Arbutus Biopharma Corp Debt Securities, Available-for-sale, Amortized Cost, Current
Arbutus Biopharma Corp (ABUS) had Debt Securities, Available-for-sale, Amortized Cost, Current of $73.38 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent · last filed 2026-03-23
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $73.38M.
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $86.24M.
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost, Current $47.42M.
- 2020-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $71.00M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Current |
|---|---|
| 2025-12-31 | $73.38M 10-K · filed 2026-03-23 |
| 2024-12-31 | $86.24M 10-K · filed 2026-03-23 |
| 2021-06-30 | $47.42M 10-Q · filed 2021-08-05 |
| 2020-12-31 | $71.00M 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |